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Abstract 
Background: Kidney disease improving global outcomes provided a new classification for chronic kidney disease 
(CKD) by subdividing the G3 stage into G3a and G3b stages based on glomerular filtration rate (GFR) in 2012. Cur-
rently, a few methods are used to evaluate GFR, including measured GFR (mGFR) and estimated GFR (eGFR). One 
of the mGFR was 99mTc-DTPA scintigraphy method and eGFR using GFR equations were used clinically. Equations 
were modification of diet in renal disease (MDRD), chronic kidney disease epidemiology collaboration (CKD-EPI), and 
Chinese adapted MDRD (C-MDRD). This study assessed the accuracy of three different equations for estimated glo-
merular filtration rate (eGFR) with mGFR using DTPA scintigraphy method as the standard in a population of Chinese 
chronic kidney disease patients at the G3a stage.
Results: One hundred and twenty-two patients (age 52.0 ± 15.6 years, 69 were male) were determined as CKD 
stage 3 based on mGFR. Patients were divided into G3a (47 patients) and G3b (75 patients) subgroups. Bias between 
eGFR for CKD-EPI and reference mGFR was 0.92 mL/min and 95% limits of agreement was −38.82 to 40.67 mL/min. 
Bias between eGFR for C-MDRD and mGFR was 3.76 and 95% limits of agreement was −39.32 to 46.85 mL/min. Bias 
between eGFR for MDRD and mGFR was 3.53 and 95% limits of agreement was −43.35 to 50.4 mL/min. The CKD-EPI 
equation showed better diagnostic value with a greater area under the receiver operating characteristic curve (AUC: 
0.763). AUC for MDRD and C-MDRD were 0.75 and 0.757, respectively.
Conclusions: There were no obvious advantages in accuracy, sensitivity, and specificity for the diagnosis of patients 
at the G3a stage using the CKD-EPI equation.
Keywords: G3a stage, Glomerular filtration rate equations, Accuracy, Chronic kidney disease
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
In 2012, kidney disease improving global outcomes pro-
vided a new classification for chronic kidney disease 
(CKD) by subdividing the G3 stage into G3a and G3b 
stages based on glomerular filtration rate (GFR). GFR for 
G3a is between 45 and 59  mL/min and GFR for G3b is 
between 30 and 44 mL/min. The risk for end-stage renal 
disease and death increased for patients at G3b more so 
than for patients at G3a. Go et al. reported the adjusted 
hazard ratio for death was 1.2 for patients at G3a (95% 
confidence interval (CI) 1.1–1.2) and 1.8 at G3b (95% 
CI 1.7–1.9) [1]. Over a median follow-up of 2.98  years, 
rates per 100 patient-years for end-stage renal disease 
were lower for G3a than G3b, at 0.6 (95% CI 0.1–1.0) vs. 
1.4 (95% CI 0.8–2.1). Death prior to end-stage renal dis-
ease for G3a was 2.2 (95% CI 1.2–3.1; p < 0.001), which 
is lower than G3b, at 4.4 (95% CI 3.3–5.6; p < 0.001) [2]. 
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Following from these classifications, it is important that 
patients are accurately assessed for G3 staging.
Currently, a few methods are used to evaluate GFR, 
including measured GFR (mGFR) and estimated GFR 
(eGFR). mGFR is determined by analysis of the clear-
ance of some exogenous markers, such as inulin, or of 
alternative exogenous markers, such as iothalamate, 
EDTA, diethylene triamine pentaacetic acid (DTPA), and 
iohexol. These methods are, however, invasive, incon-
venient, and expensive, and are unsuitable for use in 
routine clinical practice [3]. The most commonly used 
creatinine-based formulas include modification of diet 
in renal disease (MDRD) [4], chronic kidney disease epi-
demiology collaboration (CKD-EPI) [5], and the Chinese 
adapted MDRD equation (C-MDRD), the latter of which 
was validated as being more accurate than other MDRD 
equations for people of Chinese origin [6].
In this study, we compared the accuracy of eGFR using 
three equations and mGFR as the standard in Chinese 
CKD patients at the G3a stage.
Methods
Study design
This study was conducted at The First Affiliated Hospi-
tal of Zhengzhou University between June 2013 and July 
2014. It was a cross-sectional study performed at a sin-
gle center. mGFR based on 99mTc-DTPA scintigraphy 
and eGFR using the GFR equations detailed below were 
assessed. Bias, sensitivity, and specificity of eGFR were 
analyzed with mGFR in participants at the G3a stage. 
The study was approved by the Review Board of The First 
Affiliated Hospital of Zhengzhou University and all par-
ticipants provided informed consent in written format.
Population
Chinese adult inpatients with CKD between the ages of 
18 and 80 years were included. Patients who were not at 
the G3 stage based on mGFR were excluded. CKD and 
its stages were defined according to K/DOQI guidelines: 
(1) renal damage  >3  months, established by structural 
or functional damage, with or without decrease in GFR, 
shown by histological anomalies and renal damage mark-
ers, including those found in blood, urine, or images; or 
(2) GFR <60 mL/min/1.73 m2 >3 months, with or with-
out renal damage [7]. CKD was divided into five stages, 
including G3a and G3b stages.
Studies
Fasting serum creatinine, 99mTc-DTPA scintigraphy, and 
renal sonogram studies were performed. Blood samples 
and gammagraphic studies were performed at The First 
Affiliated Hospital of Zhengzhou University by the same 
professionals.
Dynamic gammagraphy with 99mTc-DTPA is regarded 
as the gold standard [8]. 99mTc-DTPA dynamic images 
were acquired using a detector of gamma camera with the 
patient in the supine position. Patients were injected with 
200 μCi/kg (at least 2 mCi) of 99mTc-DTPA and dynamic 
images were recorded in a 128 × 128 matrix format every 
second for 1 min and every 30 s for 20 min. Relative renal 
function was measured in a composite image (1–3  min 
after injection).
GFR was estimated by serum creatinine using the 
CKD-EPI equation [5], the MDRD [4] equation, and the 
C-MDRD equation [6]. Creatinine was determined using 
the dry chemistry sarcosine oxidase method with trace-
able calibration using a Roche Cobas 8000. The normal 
serum creatinine level is 20–115 µmol/L.
Equations
(Female: κ = 0.7, α = − 0.329; male: κ = 0.9, α = − 0.411; 
min indicates the minimum Scr/κ or 1, and max indicates 
the maximum Scr/κ or 1). Scr: serum creatinine.
Statistical analysis
Continuous data are expressed as mean ± standard devi-
ation or medians (25, 75%). The independent t test and 
nonparametric tests were used to compare general infor-
mation between the G3a and G3b groups. Bland–Altman 
plots were used to compare different estimates of GFR 
(bias and 95% limits of agreement). Results were consid-
ered significant if p ≤  0.05. Accuracy was calculated as 
the proportion of eGFR within 15, 30, and 50% of meas-
ured GFR (mGFR) (P15, P30, and P50, respectively). The 
McNemar test was used to compare P15, P30 and P50 
values of eGFR against P15, P30 and P50 values of mGFR. 
A receiver operating characteristic (ROC) curve was 
plotted and the area under the ROC curve (AUC) was 
calculated.
(1)
CKD-MDRD: eGFR
[
mLmin−1 (1.73m2)−1
]
= 186×
[
Scr
(
mg/dL
)]
−1.154
× age−0.203 × 0.742 (if female)
(2)
CKD-C-MDRD: eGFR
[
mLmin−1 (1.73m2)−1
]
= 175×
[
Scr
(
mg/dL
)]
−1.234
× age−0.179
× 0.79 (if female)
(3)
CKD-EPI: eGFR
[
mLmin−1 (1.73m2)−1
]
= 141×min (Scr/κ , 1)α ×max (Scr/κ , 1)−1.209
× 0.993age × 1.018 (if female)_1.159 (if black)
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Results
Four hundred and sixty-three CKD patients were 
screened. Based on results of mGFR, 122 patients (age 
52.0  ±  15.6  years, 69 were male) were determined as 
CKD stage 3 (Additional file  1). These patients were 
divided into either G3a (47 patients) or G3b stages (75 
patients). The general characteristics of the two groups 
are shown in Table  1. There were no significant dif-
ferences in age, height, body surface area, or weight 
between groups. eGFR values for G3b were lower than 
that for G3a.
Bias between eGFR_CKD-EPI and mGFR was 
0.92  mL/min and 95% limits of agreement was −38.82 
to 40.67  mL/min. Bias between eGFR_C-MDRD and 
mGFR was 3.76 and 95% limits of agreement was −39.32 
to 46.85 mL/min. Bias between eGFR_MDRD and mGFR 
was 3.53 and 95% limits of agreement was −43.35 to 
50.4 mL/min.
P15 values at the G3a stage were 38.3, 38.3, and 42.6% 
for CKD-EPI (Eq. 3), CKD-C-MDRD (Eq. 2), and CKD-
MDRD (Eq. 1), respectively (all p > 0.05) (Table 2). P30 
values at the G3a stage were 40.4, 42.6, and 44.7% for 
CKD-EPI (Eq.  3), CKD-C-MDRD (Eq.  2), and CKD-
MDRD (Eq. 1), respectively (all p > 0.05) (Table 2). P50 
values at the G3a stage were 55.4, 48.9, and 48.9% for 
CKD-EPI (Eq.  3), CKD-C-MDRD (Eq.  2), and CKD-
MDRD (Eq. 1), respectively (all p > 0.05) (Table 2).
The CKD-EPI equation (Eq. 3) showed better diagnos-
tic value, having a greater AUC (AUC: 0.763). The AUC 
for CKD-MDRD and CKD-C-MDRD were 0.75 and 
0.757, respectively (Fig. 1).
Discussion
Our study found that the bias between eGFR_CKD-EPI 
and mGFR was smaller than the other equations exam-
ined; however, there were no statistical differences in 
sensitivity, specificity, and ROC curve among the three 
equations for G3a.
The results of the current study are consistent with 
previous studies that found no significant differences in 
CKD stage 3 using different GFR equations. Levey et al. 
reported that the CKD-EPI equation was as accurate as 
the MDRD Study equation in a subgroup with an eGFR 
of less than 60 mL/min/1.73 m2. There was no difference 
between the CKD-EPI and MDRD Study equations in 
ROC curves to detect GFR <60, <45, <30, and <15 mL/
min/1.73 m2. AUC were 0.96, 0.97, 0.97, and 0.98, respec-
tively, for both equations [5]. Ma et al. found no signifi-
cant differences in the percentages of misclassifications 
between the C-MDRD and MDRD equations when 
assessing CKD stages 3–5 [6].
One possible reason for the findings may be because 
of the distribution of the CKD stage in the reference 
population. The distribution of CKD stage or mGFR of 
the enrolled patients had an influence on the resulting 
equation. However, in the development dataset of the 
C-MDRD, MDRD, and CKD-EPI equations, mGFR was 
evenly distributed in CKD stage 3. In the study by Levey 
et  al., the percentage of reference population in CKD 
stage 3 was about 33.2% [5] and in the study by Ma et al. 
the percentage was about 28.8% [6].
Creatinine value is another factor that may impact the 
accuracy of eGFR. In assessment of the three equations, 
creatinine values were either measured using the Roche 
enzymatic method or calibrated to the Roche enzymatic 
method. For the MDRD equation, serum creatinine was 
measured using a kinetic alkaline picrate assay [9] and 
the researchers re-expressed the four-variable (modi-
fied) MDRD Study equation that we used in the current 
research with the Roche enzymatic method [10]. For 
Table 1 General characteristics of  CKD patients at  the G3 
stage
Data was expressed as mean ± SD or medians (25, 75%)
G3b (30–44  
mL/min)
G3a (45–59  
mL/min)
p value
n 75 47
Age (years) 53.8 ± 15.4 49.2 ± 15.7 >0.05
Height (cm) 165.8 ± 7.0 165.7 ± 7.6 >0.05
Weight (kg) 65.9 ± 12.0 66.5 ± 10.2 >0.05
Body surface area (m2) 1.7 ± 0.2 1.7 ± 0.1 >0.05
GFR-DTPA (mL/min) 38.0 ± 4.3 52.0 ± 4.7 <0.05
GFR-EPI (mL/min) 30.0 (12.0, 40.9) 55.4 (37.2, 74.1) <0.05
GFR-MDRD (mL/min) 23.7 (10.2, 35.7) 44.3 (27.6, 61.9) <0.05
GFR-C-MDRD (mL/min) 29.1 (12.5, 43.9) 54.5 (33.9, 76.2) <0.05
Table 2 Comparison of the accuracy of different GFR equations
15% 30% 50%
G3 G3a G3b G3 G3a G3b G3 G3a G3b
CKD-EPI 41.8 38.3 54.7 50 40.4 60 56.6 55.4 62.7
CKD-C-MDRD 44.3 38.3 56 51.6 42.6 60 55.7 48.9 65.3
CKD-MDRD 44.3 42.6 57.3 51.6 44.7 58.7 55.7 48.9 65.3
p value >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
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the C-MDRD equation, creatinine levels were measured 
at a single laboratory using a Hitachi 7600 analyzer and 
Jaffe’s kinetic method. The researchers randomly selected 
57 fresh-frozen plasma samples from their specimens 
and analyzed them at both their own laboratory and the 
Cleveland Clinic Research Laboratory (Cleveland, OH, 
USA) [6]. The creatinine value at their laboratory was 
calibrated to the creatinine value measured by the Cleve-
land Clinic Research Laboratory where the MDRD Study 
samples were measured. For the CKD-EPI equation, 
for all studies, serum creatinine was recalibrated to the 
standardized creatinine measurement using the Roche 
enzymatic method (Roche-Hitachi P-Module instru-
ment with Roche Creatininase Plus assay, Hoffman-La 
Roche, Ltd., Basel, Switzerland) at the Cleveland Clinic 
Research Laboratory. For the current study, we used the 
Roche enzymatic method at our laboratory. Based on 
this, the discrepancy of eGFR caused by the creatinine 
value is less. However, the creatinine generation is associ-
ated with the muscle mass [11], and the influence of mus-
cle mass on creatinine estimation cannot be completely 
ignored.
The biases between mGFR and eGFR using the 
C-MDRD and MDRD equations are greater than that 
using the CKD-EPI equation. One possible reason may be 
mGFR data obtained using different methods, which may 
influence the bias of the different eGFR equations. The 
method used to obtain mGFR should be taken into con-
sideration when evaluating GFR estimating equations. 
The MDRD study used renal clearance of 125I-iothala-
mate, the Chinese study used plasma clearance of 99mTc-
DTPA, and the CKD-EPI group used iothalamate in the 
development of datasets. Chen et  al. and Shanshan Dai 
et  al. confirmed that GFR measured by 99mTc-DTPA 
plasma clearance and 99mTc-DTPA dynamic imaging 
significantly overestimates GFR when compared with 
inulin clearance, especially in groups with low GFR, low 
body mass index, and a younger age [12, 13]. Soveri et al. 
suggested that renal clearance of DTPA, renal clearance 
of iohexol, and plasma clearance of inulin had sufficient 
accuracy (limited evidence) [14]. The muscle mass may 
also contributed to the accuracy of CKD-EPI equation 
[5]. Because the average muscle mass among healthy per-
sons in the cohort of CKD-EPI equation was higher than 
other equations, and the CKD-EPI equation includes the 
indicators of age, race and sex and these variables are 
associated with muscle mass.
There are some limitations of this study. First, this is 
a single center study, and a multi-center study is neces-
sary to validate the results. Second, though the CKD-
EPI equation showed less bias in the G3a stage, but this 
equation could not avoid the disadvantage of serum 
creatinine, that the value of serum creatinine would be 
affected by the muscle mass. And Segarra et  al. suggest 
that the use of equations based on cystatin C (CysC) is 
more appropriate in hospitalized patients to estimate 
GFR, since these equations are much less dependent on 
patient’s nutritional status or muscle mass than the CKD-
EPI equation [15]. We will explore the accuracy of eGFR 
equations based on CysC in the G3a stage.
Conclusions
The bias between mGFR and eGFR using the CKD-EPI 
equation at the G3a stage was less than that for the other 
two equations. However, there was no obvious advantage 
in accuracy, sensitivity, and specificity for diagnosis at the 
G3a stage using the CKD-EPI equation.
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